Coronary Artery Disease and Myocardial Infarction

Sean Fitzgerald , Maria Rubini Gimenez , Abdelhakim Allali , et al

Read time: 17 Mins

Ahmet Fuat, Gary Ford, Kausik Ray, et al

AHA 22: RESPECT EPA: Eicosapentaenoic Acid for Prevention of Coronary Artery Disease

Hiroyuki Daida, Saahil A Jumkhawala,

Watch time: 14m 14s
AHA 22 Late-Breaker Discussion: The PRECISE Trial

Pamela S Douglas, Harriette Van Spall,

Watch time: 14m 57s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 29s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 25s
EP 78: Your Guide to Lipoprotein(a) with Dr. Salim S Virani

Salim S Virani, Ankur Kalra,

Listen time: 46:28
TCT 22: FAME 3: FFR-Guided PCI Vs CABG in Pts With Multivessel CAD

Yuhei Kobayashi,

Watch time: 07:21
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: The Trial in Context

Marc S Sabatine,

Watch time: 3m 24s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s
ESC 22: 18F-NaF PET for Vulnerable Coronary Plaque imaging After MI

David Newby,

Watch time: 3:22

Paul M Ridker, Aernoud Fiolet, Jean-Claude Tardif, et al

Heather Currie , Christine Williams ,

, Carlo Savini , Marco Di Eusanio ,

Edward T Carreras , Donna M Polk ,

Sivabaskari Pasupathy , Rosanna Tavella , Simon McRae , et al

FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s

Hans-Willi Breuer ,

Remo Albiero ,

FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Astrid Hubert , Andreas Seitz , Valeria Martínez Pereyra , et al

Kevin Cheng , Paul Sainsbury , Michael Fisher , et al

Kamal Chitkara , Anthony H Gershlick ,

Media

Ahmet Fuat, Gary Ford, Kausik Ray, et al

Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 29s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 25s
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: The Trial in Context

Marc S Sabatine,

Watch time: 3m 24s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s
ESC 22: ALL-HEART: Allopurionol in the Treatment of Ischaemic Heart Disease

Isla Mackenzie,

Watch time: 2:27

Yassir Javaid, Nina Barnett, Paresh Parmar, et al

Watch time: 1h 6m (4 videos)

Prof Lale Tokgozoglu, Kausik Ray, Maciej Banach, et al

Paul M Ridker, Aernoud Fiolet, Jean-Claude Tardif, et al

Maciej Banach, Yassir Javaid, Lale Tokgözoğlu, et al

Watch time: 1:27:02
ACC 2022 Late-breaker Discussion: The SuperWIN Trial

Dylan L Steen, Harriette Van Spall,

UZ Clear Finds 50% Patients with Angina Have Evidence of CAD

Carlos Collet,

Zsolt Piroth, Hitoshi Matsuo, Evald Høj Christiansen, et al

Barbara Stähli , Stephan Kische, Tommaso Gori, et al

Guy Van Camp, Koen Van Bockstal, Enrico Neri, et al

RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes

Nick Curzen,

ACC 2021: Findings From the RESCUE Trial

Paul M Ridker,

AHA 2020: Findings from the THALES trial — Prof Pierre Amarenco

Pierre Amarenco,

TCT Connect 2020 Discussion: The VOYAGER PAD Study

Mirvat Alasnag, Connie N Hess,

ESC 2020: Final Results of the EVAPORATE Trial

Matthew J Budoff,

ACC 2020 Wrap Up: An Analysis of the Late-breaking Trials

Joost Daemen, Nicolas M Van Mieghem,

ESC 2015 : Ethnic Differences in Incidences of Coronary Artery Spasm

Hiroaki Shimokawa,

Media

Ahmet Fuat, Gary Ford, Kausik Ray, et al

AHA 22: RESPECT EPA: Eicosapentaenoic Acid for Prevention of Coronary Artery Disease

Hiroyuki Daida, Saahil A Jumkhawala,

Watch time: 14m 14s
AHA 22 Late-Breaker Discussion: The PRECISE Trial

Pamela S Douglas, Harriette Van Spall,

Watch time: 14m 57s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 29s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 25s
EP 78: Your Guide to Lipoprotein(a) with Dr. Salim S Virani

Salim S Virani, Ankur Kalra,

Listen time: 46:28
TCT 22: FAME 3: FFR-Guided PCI Vs CABG in Pts With Multivessel CAD

Yuhei Kobayashi,

Watch time: 07:21
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: The Trial in Context

Marc S Sabatine,

Watch time: 3m 24s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s
ESC 22: 18F-NaF PET for Vulnerable Coronary Plaque imaging After MI

David Newby,

Watch time: 3:22
ESC 22: ALL-HEART: Allopurionol in the Treatment of Ischaemic Heart Disease

Isla Mackenzie,

Watch time: 2:27

Yassir Javaid, Nina Barnett, Paresh Parmar, et al

Watch time: 1h 6m (4 videos)

Prof Lale Tokgozoglu, Kausik Ray, Maciej Banach, et al

EuroPCR 22: ROLEX Study Finds Promising Results in CAD Pts With the Resolute Onyx

Giuseppe Tarantini,

Juan Carlos Kaski, Aernoud Fiolet,

Juan-Pablo Kaski, Peter Libby,

Juan Carlos Kaski, Lina Badimon,

Targeting Inflammation in Atherosclerosis: Inflammatory Signalling in Atherosclerosis and CKD

Juan Carlos Kaski, Paul M Ridker,

Targeting Inflammation in Atherosclerosis: Unmet Clinical Needs in Atherosclerosis and Chronic Kidney Disease

Juan Carlos Kaski, Paul M Ridker,

Jean-Claude Tardif,

Targeting Inflammation in Atherosclerosis: LoDoCo2 Trial

Aernoud Fiolet,

4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos

Erin D Michos,

Targeting Inflammation in Atherosclerosis: RESCUE Trial

Peter Libby,

Targeting Inflammation in Atherosclerosis: CANTOS Trial

Paul M Ridker,

Paul M Ridker, Aernoud Fiolet, Jean-Claude Tardif, et al

Maciej Banach, Yassir Javaid, Lale Tokgözoğlu, et al

Watch time: 1:27:02
Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events

Paul M Ridker,

ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab

Lorenz Räber,

ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)

Steven E Nissen,

Articles

Sex Differences in Calcified Coronary Lesions

Sean Fitzgerald

,

Maria Rubini Gimenez

,

Abdelhakim Allali

,

Ralph Toelg

,

Dmitriy S. Sulimov

,

Volker Geist

,

Adnan Kastrati

,

Holger Thiele

,

Gert Richardt

,

Mohamed Abdel-Wahab

,

Published:

20 January 2023

Citation:

Interventional Cardiology 2023;18:e02.

DOI:

https://doi.org/10.15420/icr.2022.07
  • Views: Views 16
  • Downloads: Downloads 2
  • Read time: 17 Mins

Rotatripsy in Left Main Disease

Dinakar Bootla

,

Pruthvi C Revaiah

,

Navjyot Kaur

,

Yash Paul Sharma

,

Himanshu Gupta

,

Published:

25 May 2022

Citation:

Journal of Asian Pacific Society of Cardiology 2022;1:e13.

DOI:

https://doi.org/10.15420/japsc.2021.24
  • Views: Views 596
  • Downloads: Downloads 26
  • Citations: 1
  • Read time: 11 minutes

Lipoprotein(a) and Cardiovascular Disease

Yoshiyasu Minami

,

Daisuke Kinoshita

,

Yusuke Muramatsu

,

Takako Nagata

,

Junya Ako

,

Published:

13 May 2022

Citation:

Journal of Asian Pacific Society of Cardiology 2022;1:e11.

DOI:

https://doi.org/10.15420/japsc.2021.31
  • Views: Views 805
  • Downloads: Downloads 52

Prevalence of CYP2C19 Gene Polymorphism in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

Maya Rosana Amalia

,

Susi Herminingsih

,

Published:

14 December 2021

Citation:

European Cardiology Review 2021;16:e61.

DOI:

https://doi.org/10.15420/ecr.2021.16.PO5
  • Views: Views 299
  • Downloads: Downloads 12